Smiljanic Tomicevic L, Baresic M, Mayer M, Anic B
Acta Clin Croat. 2025; 62(4):714-723.
PMID: 39866764
PMC: 11759123.
DOI: 10.20471/acc.2023.62.04.18.
Yin H, Li L, Feng X, Wang Z, Zheng M, Zhao J
Signal Transduct Target Ther. 2024; 9(1):323.
PMID: 39551768
PMC: 11570697.
DOI: 10.1038/s41392-024-02017-6.
Lin Z, Jiang B, Wang W, Chen C, Wang Y, Wan J
PeerJ. 2024; 12:e18028.
PMID: 39308826
PMC: 11416754.
DOI: 10.7717/peerj.18028.
Tanveer S, Pan C, Sami F, Romero Noboa M, Cornejo Gonzalez D, Patolia K
Cureus. 2024; 16(7):e65302.
PMID: 39184747
PMC: 11343638.
DOI: 10.7759/cureus.65302.
Lee Y, Ahn S, Hong S, Oh J, Lee C, Yoo B
Korean J Intern Med. 2023; 39(2):338-346.
PMID: 38031366
PMC: 10918380.
DOI: 10.3904/kjim.2023.229.
Readministration of high-dose adeno-associated virus gene therapy vectors enabled by ImmTOR nanoparticles combined with B cell-targeted agents.
Ilyinskii P, Roy C, Michaud A, Rizzo G, Capela T, Leung S
PNAS Nexus. 2023; 2(11):pgad394.
PMID: 38024395
PMC: 10673641.
DOI: 10.1093/pnasnexus/pgad394.
Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M, Nikolopoulos D, Koutsoviti S, Flouri I, Kapsala N, Repa A
Front Immunol. 2023; 13:1074044.
PMID: 36685524
PMC: 9845912.
DOI: 10.3389/fimmu.2022.1074044.
Effect and safety profile of belimumab and tacrolimus combination therapy in thirty-three patients with systemic lupus erythematosus.
Nakai T, Fukui S, Kidoguchi G, Ikeda Y, Kitada A, Nomura A
Clin Rheumatol. 2022; 41(12):3735-3745.
PMID: 35939162
DOI: 10.1007/s10067-022-06325-6.
Systemic Lupus Erythematosus-Associated Serositis Managed With Intravenous Belimumab: A Case Report.
Mukkera S, Mannem M, Chamarti K, Pillarisetty L, Vulasala S, Alahari L
Cureus. 2022; 14(2):e22639.
PMID: 35242484
PMC: 8884522.
DOI: 10.7759/cureus.22639.
Antibody Therapies in Autoimmune Neuromuscular Junction Disorders: Approach to Myasthenic Crisis and Chronic Management.
Vanoli F, Mantegazza R
Neurotherapeutics. 2022; 19(3):897-910.
PMID: 35165857
PMC: 9294078.
DOI: 10.1007/s13311-022-01181-3.
Emerging B-Cell Therapies in Systemic Lupus Erythematosus.
Bag-Ozbek A, Hui-Yuen J
Ther Clin Risk Manag. 2021; 17:39-54.
PMID: 33488082
PMC: 7814238.
DOI: 10.2147/TCRM.S252592.
Management of End-stage Renal Disease Associated with Systemic Rheumatic Diseases.
Honda S, Katsumata Y, Karasawa K, Yamanaka H, Harigai M
JMA J. 2020; 3(1):20-28.
PMID: 33324772
PMC: 7733740.
DOI: 10.31662/jmaj.2019-0020.
BAFF 60-mer, and Differential BAFF 60-mer Dissociating Activities in Human Serum, Cord Blood and Cerebrospinal Fluid.
Eslami M, Meinl E, Eibel H, Willen L, Donze O, Distl O
Front Cell Dev Biol. 2020; 8:577662.
PMID: 33240880
PMC: 7677505.
DOI: 10.3389/fcell.2020.577662.
Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies.
Petricca L, Gigante M, Paglionico A, Costanzi S, Vischini G, Di Mario C
Front Med (Lausanne). 2020; 7:553075.
PMID: 33195302
PMC: 7657367.
DOI: 10.3389/fmed.2020.553075.
Management of Pediatric Systemic Lupus Erythematosus: Focus on Belimumab.
Guzman M, Hui-Yuen J
Drug Des Devel Ther. 2020; 14:2503-2513.
PMID: 32612353
PMC: 7323799.
DOI: 10.2147/DDDT.S216193.
Additive Therapeutic Effects of Mesenchymal Stem Cells and IL-37 for Systemic Lupus Erythematosus.
Xu J, Chen J, Li W, Lian W, Huang J, Lai B
J Am Soc Nephrol. 2019; 31(1):54-65.
PMID: 31604808
PMC: 6935004.
DOI: 10.1681/ASN.2019050545.
Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review.
Samotij D, Reich A
Biomed Res Int. 2019; 2019:8142368.
PMID: 31396534
PMC: 6668536.
DOI: 10.1155/2019/8142368.
Therapeutic effects of a novel BAFF blocker on arthritis.
Zhou B, Zhang H, Su X, Luo Y, Li X, Yu C
Signal Transduct Target Ther. 2019; 4:19.
PMID: 31231554
PMC: 6565627.
DOI: 10.1038/s41392-019-0051-z.
Skin-Associated B Cells in Health and Inflammation.
Debes G, McGettigan S
J Immunol. 2019; 202(6):1659-1666.
PMID: 30833422
PMC: 6402607.
DOI: 10.4049/jimmunol.1801211.
Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
Beecher G, Putko B, Wagner A, Siddiqi Z
Drugs. 2019; 79(4):353-364.
PMID: 30762205
DOI: 10.1007/s40265-019-1065-0.
